For more information on Age-Related Macular Degeneration go to the NHS website. If you've had a diagnosis, in addition to ...

MCLEAN, Va., Feb. 04, 2025 (GLOBE NEWSWIRE) -- (TLI), a not-for-profit organization that works at the nexus of science, ...

Macular degeneration is one of the leading causes of vision loss, affecting millions worldwide, especially those over 60.

The U.S. Food and Drug Administration has approved Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular edema.

The unique challenges, and need for awareness, of age-related macular degeneration (AMD) is now formally recognized in Canada ...

Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema: Basel Thursday, February 6, 2025, 11:00 Hrs [IST] Roche announced that the US Food and Drug ...

Study from Case Western Reserve University and VA Northeast Ohio Healthcare System examines genetic risk profiles across ...

Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a ...

The U.S. Food and Drug Administration (FDA) has approved ranibizumab injection (Susvimo, 100 mg/mL; Genentech) for the ...

Introduction The eye's macula is impacted by macular degeneration, a neurodegenerative condition. Macular degeneration will cause loss of centr ...

In response to the TGA's approval of a new drug to treat macular degeneration, UNSW researcher Dr Lisa Nivison-Smith provides context about the ...

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...